{"log_id": 4592740444756025358, "direction": 0, "words_result_num": 35, "words_result": [{"probability": {"variance": 0.029069, "average": 0.855888, "min": 0.386487}, "location": {"width": 1302, "top": 178, "height": 54, "left": 196}, "words": "药,年且之后过行治疗药监测以达到和维持谷浓度在S1ngml参见【网注用量】“排荐剂量”和“治"}, {"probability": {"variance": 0.003438, "average": 0.969165, "min": 0.826792}, "location": {"width": 187, "top": 237, "height": 34, "left": 196}, "words": "疗药物监测”)"}, {"probability": {"variance": 0.002821, "average": 0.95557, "min": 0.85475}, "location": {"width": 153, "top": 345, "height": 36, "left": 189}, "words": "【老年月药"}, {"probability": {"variance": 0.025908, "average": 0.898249, "min": 0.383499}, "location": {"width": 1248, "top": 400, "height": 48, "left": 249}, "words": "在其它两项机究晚细胞痛和晚期胰神经内分泌》中发现,老年思者与相对年轻患者之间"}, {"probability": {"variance": 0.029168, "average": 0.88963, "min": 0.382436}, "location": {"width": 1293, "top": 450, "height": 52, "left": 198}, "words": "的疗效总体上井无差异、在晚湖肾细胞随机研究,品治疗患者41为65岁,其中了为≥75岁。在"}, {"probability": {"variance": 0.036453, "average": 0.869202, "min": 0.424272}, "location": {"width": 1026, "top": 507, "height": 48, "left": 194}, "words": "晚胰腺神经内分泌随机研究中,本治疗患者30%为≥n5岁,其中7三7"}, {"probability": {"variance": 0.01947, "average": 0.929294, "min": 0.477385}, "location": {"width": 1241, "top": 562, "height": 50, "left": 251}, "words": "其它临床试验中也突照送年怎与对年轻患者之间存在疗效差异,但不能排除某老年个体有较高的"}, {"probability": {"variance": 0.012961, "average": 0.917811, "min": 0.633909}, "location": {"width": 374, "top": 619, "height": 34, "left": 196}, "words": "敏感性(参见【药代动力学1)"}, {"probability": {"variance": 0.026643, "average": 0.901783, "min": 0.398644}, "location": {"width": 1186, "top": 672, "height": 48, "left": 249}, "words": "在老年患者中不进行剂素询整,但建议密刀监测不良反应透当地剂整(参见约代动力学】"}, {"probability": {"variance": 0.00013, "average": 0.988313, "min": 0.961871}, "location": {"width": 212, "top": 774, "height": 34, "left": 180}, "words": "【药物相互作用】"}, {"probability": {"variance": 0.022203, "average": 0.888471, "min": 0.422004}, "location": {"width": 1243, "top": 827, "height": 50, "left": 249}, "words": "依线莫司是CYP3A4底物,也是多种药物外排PgP的底物和中效抑制剂。在体外,维英司是CYP3A4"}, {"probability": {"variance": 0.026803, "average": 0.872759, "min": 0.500314}, "location": {"width": 496, "top": 886, "height": 32, "left": 192}, "words": "的竞学检制剂和CYP2D6的混合抑制剂"}, {"probability": {"variance": 0.018774, "average": 0.922788, "min": 0.507125}, "location": {"width": 393, "top": 941, "height": 34, "left": 194}, "words": "可开高依维莫司血药浓度的药物"}, {"probability": {"variance": 0.04181, "average": 0.766071, "min": 0.383004}, "location": {"width": 361, "top": 996, "height": 34, "left": 196}, "words": "CVP3A抑剂PgP"}, {"probability": {"variance": 0.014747, "average": 0.914789, "min": 0.577144}, "location": {"width": 1206, "top": 1049, "height": 43, "left": 242}, "words": "在健康受试者中,与单独使用本品相比较,本品与下列药物合并使用时依维点司的暴露量显著培加"}, {"probability": {"variance": 0.03718, "average": 0.845385, "min": 0.35607}, "location": {"width": 1060, "top": 1104, "height": 43, "left": 313}, "words": "康唑(强CYP3A4抑制剂和里P抑制剂)Cmx和AUC分别增加3.9倍和15.0倍"}, {"probability": {"variance": 0.021719, "average": 0.899282, "min": 0.446038}, "location": {"width": 1046, "top": 1158, "height": 43, "left": 313}, "words": "红索(CYP3A4仰制和PgP排制剂),Cmx和ALC分别剪加2.0倍和4.4倍"}, {"probability": {"variance": 0.031737, "average": 0.872356, "min": 0.375423}, "location": {"width": 1076, "top": 1213, "height": 43, "left": 308}, "words": "维拉米(中效CYP3A4剂PgP抑制剂),Cm3AUC分别增加2.3倍和3.5倍"}, {"probability": {"variance": 0.018125, "average": 0.902404, "min": 0.519346}, "location": {"width": 918, "top": 1268, "height": 36, "left": 242}, "words": "不应与CYP3A4强效扣制剂合美用药《参见【用法用】和【注意事项】"}, {"probability": {"variance": 0.012331, "average": 0.931378, "min": 0.461577}, "location": {"width": 1236, "top": 1325, "height": 38, "left": 242}, "words": "本品应慎与中效CYP3A4和或PgP抑制合用。如小能选择治疗,应降低本品剂录(参见【用法用"}, {"probability": {"variance": 0.028351, "average": 0.854089, "min": 0.582273}, "location": {"width": 269, "top": 1378, "height": 34, "left": 185}, "words": "量】和【注意项】)"}, {"probability": {"variance": 0.031713, "average": 0.909755, "min": 0.466384}, "location": {"width": 395, "top": 1433, "height": 34, "left": 185}, "words": "可降低依维莫司血药浓度的药物"}, {"probability": {"variance": 0.024103, "average": 0.665619, "min": 0.426894}, "location": {"width": 155, "top": 1488, "height": 34, "left": 217}, "words": "P3A4导剂"}, {"probability": {"variance": 0.027434, "average": 0.885559, "min": 0.452916}, "location": {"width": 1241, "top": 1540, "height": 43, "left": 237}, "words": "在健康受试者中,与单独使用依痘莫可相比较,品与利福平(P3A4致诱导剂)合使用时,依"}, {"probability": {"variance": 0.015432, "average": 0.932853, "min": 0.364128}, "location": {"width": 1266, "top": 1595, "height": 43, "left": 182}, "words": "维莫AUC和Cx分别降低63和58本品与CYP3A4或PgP强效导剂合并使用时,如不能选择治疗"}, {"probability": {"variance": 0.019919, "average": 0.912148, "min": 0.524841}, "location": {"width": 1202, "top": 1652, "height": 36, "left": 180}, "words": "应考虑增加本品剂量约翰草会不预踢地降低依维莫露量,应避免使用(参见【用法用量】"}, {"probability": {"variance": 0.023881, "average": 0.92132, "min": 0.395376}, "location": {"width": 416, "top": 1709, "height": 32, "left": 187}, "words": "可被依莫司改变药浓度的药物"}, {"probability": {"variance": 0.025323, "average": 0.882993, "min": 0.427803}, "location": {"width": 1241, "top": 1764, "height": 36, "left": 235}, "words": "健受试者研究显示,在本品与羧甲基戊二单酰轴酶A门MG-CoA还原酶抑制阿托戈他汀(CYP3A4"}, {"probability": {"variance": 3e-06, "average": 0.99683, "min": 0.995059}, "location": {"width": 54, "top": 1821, "height": 29, "left": 180}, "words": "底物"}, {"probability": {"variance": 0.028385, "average": 0.916609, "min": 0.359881}, "location": {"width": 1186, "top": 1819, "height": 38, "left": 290}, "words": "伐他汀(丰CYP3A4底物)之间没有具临因意义的药代力学相互作用,体药代动力学分析也"}, {"probability": {"variance": 0.01558, "average": 0.905383, "min": 0.553858}, "location": {"width": 740, "top": 1874, "height": 34, "left": 178}, "words": "没有检测到辛伐他汀CYP3A4底物)影响本品请除的情况"}, {"probability": {"variance": 0.020454, "average": 0.921519, "min": 0.358285}, "location": {"width": 1238, "top": 1927, "height": 38, "left": 230}, "words": "在健感受试老中进行的研究结果显示:同时口服咪达仑(敏感的CYP3A4底物)和依维莫司导致咪达"}, {"probability": {"variance": 0.019414, "average": 0.874103, "min": 0.535033}, "location": {"width": 580, "top": 1981, "height": 34, "left": 180}, "words": "端仑C上升25%,咪达仓AC上30%"}, {"probability": {"variance": 0.030669, "average": 0.900691, "min": 0.364912}, "location": {"width": 1238, "top": 2036, "height": 38, "left": 230}, "words": "依维莫司与长效奥曲合用时,曲Cm上升约50%。这个升高对晚期神经内分泌瘤患者使用依"}, {"probability": {"variance": 0.044892, "average": 0.831538, "min": 0.443604}, "location": {"width": 502, "top": 2093, "height": 34, "left": 173}, "words": "菜闰的疗效反成没有临床显的影"}], "language": 3}